Lv4
430 积分 2025-02-13 加入
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
5小时前
待确认
Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC
1天前
已完结
Management of Heart Failure With Improved Ejection Fraction
4天前
已完结
Global burden of heart failure: a comprehensive and updated review of epidemiology
4天前
已完结
Prognostic significance of C-reactive protein-albumin-lymphocyte (CALLY) index after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction
5天前
已完结
Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists
18天前
已完结
Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists
19天前
已完结
GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors
19天前
已完结
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
19天前
已完结
The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis
24天前
已完结
皖公网安备34019202002308
